Antithrombotic agents in coronary artery disease

Chest

Volumn 119, Issue 1 SUPPL., 2001, Pages 228S-252S

  Cairns, J A ^a   Theroux P ^a   Lewis H D , Jr ^a   Ezekowitz, M ^a   Meade, T W ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACENOCOUMAROL; ACETYLSALICYLIC ACID; ANISTREPLASE; ANTICOAGULANT AGENT; CLOPIDOGREL; DIPYRIDAMOLE; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; ISIS 265; LAMIFIBAN; PHENPROCOUMON; RIDOGREL; SULFINPYRAZONE; TICLOPIDINE; TIROFIBAN; TRAPIDIL; TRIFLUSAL; WARFARIN; XEMILOFIBAN;

ANTICOAGULANT THERAPY; BLEEDING; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; HEART REINFARCTION; HUMAN; LIVER DYSFUNCTION; LUNG EMBOLISM; MORTALITY; NEUTROPENIA; PATHOGENESIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; STROKE; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

EID: 0035125570     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.119.1_suppl.228S     Document Type: Conference Paper

References (154)

1. Significance of paroxysmal atrial fibrillation complicating acute myocardial infarction in the thrombolytic era
2. Left ventricular mural thrombi complicating acute myocardial infarction: Long-term follow-up with serial echocardiography
3. Detection of active left ventricular thrombosis during acute myocardial infarction using indium-111 platelet scintigraphy
4. Left ventricular thrombosis and cerebrovascular accident in acute myocardial infarction
5. Mural thrombi in myocardial infarctions: Prospective evaluation of two-dimensional echocardiography
6. Incidence of left-ventricular thrombosis after acute transmural myocar dial infarction: Serial evaluation by two-dimensional echo cardiography
7. Prognostic significance and natural history of left ventricular thrombi in patients with acute anterior myocardial infarction: A two-dimensional echo cardiographic study
8. Comparative value of invasive and noninvasive techniques for identifying left ventricular mural thrombi
9. Effects of full-dose heparin anticoagulation on the development of left ventricular thrombosis in acute transmural myocardial infarction
10. Embolic potential of left ventricular thrombus after myocardial infarction: A two-dimensional echocardiographic study of 119 patients
11. Embolic potential of left ventricular thrombi detected by two-dimensional echocardiography
12. Preoperative two-dimensional echocardiographic evaluation of left ventricular chamber wall embolism after acute myocardial infarction
13. Increased embolic risk in patients with left ventricular thrombi
14. Clinical correlations in patients with acute myocardial infarction and left ventricular thrombus detected by two-dimensional echocardiography
15. Embolic potential, prevention and management of mural thrombus complicating anterior myocardial infarction: A meta-analysis
16. Assessment of short-term anticoagulant administration after cardiac infarction: Report of the working party on anticoagulant therapy in coronary thrombosis to the medical research council
17. Anticoagulant therapy after acute myocardial infarction: Relation of therapeutic benefit to patient's age, sex and severity of infarction
18. Anticoagulants in acute myocardial infarction: Results of a cooperative clinical trial
19. Comparison of high-dose with low-dose subcutaneous heparin to prevent left ventricular mural thrombosis in patients with acute transmural anterior myocardial infarction
20. Randomized trial of low molecular weight heparin (dalteparin) in prevention of left ventricular thrombus formation and arterial embolism after acute anterior myocardial infarction: The Fragmin in Acute Myocardial Infarction (FRAMI) study
21. Randomized controlled trial of subcutaneous calcium-heparin in acute myocardial infarction
22. Left ventricular thrombus in anterior acute myocardial infarction after thrombolysis: A GISSI-2 connected study
23. Atrial fibrillation in the setting of acute myocardial infarction: The GUSTO-1 experience; global utilization of streptokinase and tPA for occluded coronary arteries
24. Ischemic stroke after myocardial infarction: A population based study
25. Ventricular dysfunction and the risk of stroke after myocardial infarction
26. Warfarin anticoagulation and survival
27. Antiplatelet agents and survival: A cohort analysis from the Studies of Left Ventricular Dysfunction (SOLVD) Trial
28. Mural thrombus in left ventricular aneurysm: Incidence, role of angiography, and relation between anticoagulation and embolization
29. Prevalence of mural thrombi and systemic embolization with left ventricular aneurysm: Effect of anticoagulant therapy
30. Systemic embolization in chronic left ventricular aueurysm: Incidence and the role of anticoagulation
31. Evidence favoring the use of anticoagulants in the hospital phase of acute myocardial infarction
32. Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: Systematic overview of randomized trials
33. Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction
34. Coronary occlusion treated with small doses of heparin
35. Anticoagulants in acute myocardial infarction
36. Myocardial infarction and deep-vein thrombosis
37. Heparin in the prevention of deep-vein thrombosis after myocardial infarction
38. Antithrombotic agents in coronary artery disease
39. Reperfusion adjunctive therapy: Heparin
40. Plasma fibrinopeptide A levels in patients with acute myocardial infarction treated with alteplase: Correlation with concomitant heparin, coronary artery patency, and recurrent ischemia
41. ISIS-3: A randomized comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction
42. GISSI-2: A factorial randomized trial of alteplase and heparin versus no heparin among 12,490 patients with acute myocardial infarction
43. In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomized between alteplase and streptokinase with or without heparin
44. Long-term anticoagulant therapy, after myocardial infarction: A study of 747 patients in 15 hospitals
45. Long-term anticoagulant therapy after myocardial infarction: Final report of the Veterans Administration Cooperative Study
46. An assessment of long-term anticoagulant administration after cardiac infarction
47. The German-Austrian Aspirin trial: A comparison of acetylsalicylic acid, placebo and phenprocoumon in secondary prevention of myocardial infarction
48. Collaborative analysis of long-term anticoagulant administration after acute myocardial infarction
49. A double-blind trial to assess long-term anticoagulant therapy in elderly patients after myocardial infarction: Report of the Sixty Plus Reinfarction Study Research Group
50. Risks of long-term anticoagulant therapy in elderly patient after myocardial infarction
51. The effect of warfarin on mortality and reinfarction after myocardial infarction
52. Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction
53. Oral anticoagulants are effective long-term after acute myocardial infarction
54. Effectiveness of low-dose heparin in prevention of myocardial infarction
55. Clinical pharmacology of platelet inhibitors
56. Platelet aggregation in partially obstructed vessels and its elimination with aspirin
57. A randomized, blinded trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE)
58. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine
59. Blockade of platelet GPIIb/IIIa receptors as an antithrombotic strategy
60. A randomized controlled trial of aspirin in the prevention of early mortality in myocardial infarction
61. Early use of aspirin
62. Randomized factorial trial of high-dose intravenous streptokinase, of oral aspirin and of intravenous heparin in acute myocardial infarction
63. Low dose aspirin after early thrombolysis in anterior wall acute myocardial infarction
64. Aspirin versus Coumadin in the prevention of reocclusion and recurrent ischemia after successful thrombolysis: A prospective placebo-controlled angiographic study: Results of the APRICOT study
65. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2
66. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty
67. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty: Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis
68. Randomized placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction
69. 2 prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction
70. Collaborative overview of randomized trials of antiplatelet therapy: I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
71. United Kingdom Transient Ischemic Attack (UK-TIA) Aspirin Trial: Interim results
72. 2 but not of systemic prostacyclin by controlled-release aspirin
73. Sulfinpyrazone in the prevention of sudden death after myocardial infarction: The Anturane Reinfarction Trial
74. Sulfinpyrazone in the prevention of sudden death after myocardial infarction
75. The FDAs critique of the Anturane Reinfarction Trial
76. Sulfinpyrazone in the post-myocardial infarction: Report from the Anturane Reinfarction Italian Study
77. Persantine and aspirin in coronary heart disease
78. Persantine-Aspirin Reinfarction Study: II. Secondary coronary prevention with persantine and aspirin
79. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke
80. A randomized trial comparing ticlopidine hydrochloride with aspirin for the presentation of stroke in high-risk patients
81. Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine: Results from STIMS, the Swedish Ticlopidine Multicentre Study
82. Effects of aspirin and trapidil on cardiovascular events after acute myocardial infarction: Japanese Antiplatelet Myocardial Infarction Study (JAMIS) Investigators
83. The Evaluation of Xemilofiban in Controlling Thrombotic Events (EXCITE) trial: 30-Day and six-month results
84. Oral glycoprotein IIb/IIIa inhibiiton with orofiban in patients with unstable coronary syndromes (OPUS-TIMI16) trial
85. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: A randomized trial: Sibrafiban versus aspirin to yield maximum protection from ischemic heart events post-acute coronary syndromes
86. Secondary prevention of myocardial infarction: A comparison of acetylsalicylic acid, placebo and phenprocoumon
87. A controlled comparison of aspirin and oral anticoagulants in prevention of death after myocardial infarction
88. A comparison of aspirin and anticoagulation following thrombolysis for myocardial infarction (the AFTER study): A multicentre unblinded randomized clinical trial
89. Randomized, double-blind trial of fixed low dose warfarin with aspirin after myocardial infarction
90. Randomized trial of low intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischemic heart disease in men at increased risk: The Medical Research Council's General Practice Research Framework Thrombosis Prevention Trial
91. Combination, hemotherapy and mortality prevention (CHAMP) rates of major hemorrhage
92. Oral anticoagulant therapy in patients with coronary artery disease: A meta-analysis
93. One year mortality outcomes of all coronary and intensive care unit patients with acute myocardial infarction, unstable angina, or other chest pain in Hamilton, Ontario, a city of 375,000 people
94. Long-term benefit of early thrombolytic therapy in patients with acute myocardial infarction: 5 Year follow-up of a trial conducted by the Interuniversity Cardiology Institute of the Netherlands
95. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: Analysis of pooled data from five randomized controlled trials
96. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina: Results of Veterans Administration Cooperative Study
97. Aspirin, sulfinpyrazone, or both, in unstable angina: Results of a Canadian multicentre clinical trial
98. Aspirin, heparin, or both to treat acute unstable angina
99. Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina
100. Risk of myocardial infarction and death during treatment with low-dose aspirin and intravenous heparin in men with unstable coronary artery disease
101. Protective effects of triflusal against myocardial infarction in patients with unstable angina: Results of a Spanish multicenter trial
102. Antiplatelet treatment with ticlopidine in unstable angina: A controlled multicenter trial
103. Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE trial
104. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels: C7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators
105. A randomized trial of potent platelet IIb/IIIa antagonism, heparin, or both, in patients with unstable angina: The PARAGON Study
106. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina
107. Troponin elevation for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban
108. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction
109. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes
110. Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: Early benefit during medical treatment only, with additional protection during percutaneous coronary intervention
111. Economic assessment of tirofiban in the management of acute coronary syndromes in the hospital setting
112. Trial of heparin versus atenolol in prevention of myocardial infarction in intermediate coronary syndrome
113. Anticoagulant treatment in unstable angina
114. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina
115. Comparison of the effect of heparin and aspirin versus aspirin alone on transient myocardial ischemia and in-hospital prognosis in patients with unstable angina
116. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users: Primary end point analysis from the ATACS trial
117. Reactivation of unstable angina following discontinuation of heparin
118. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia
119. Low-molecular-weight heparin during instability in coronary artery disease
120. Low-molecular weight heparins
121. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease
122. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease
123. Enoxaparin prevents death and cardiac ischemic evens in unstable angina/non-Q-wave myocardial infarction: Results of the Thrombolysis In Myocardial Infarction (TIMI) 11B trial
124. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6 day treatment of unfractinated heparin in the initial management of unstable angina or non-Q-wave myocardial infarction: FRAXIS (FRAXiparine in Ischemic Syndrome)
125. Assessment of the treatment effect of enoxaparin for unstable angina/non-Qwave myocardial infarction: TIMI 11B-ESSENCE meta-analysis
126. Economic assessment of low molecular weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: Results from the ESSENCE randomized trial: Efficacy and Safety of Subcutaneous Enoxaparin in Non-Qwave Coronary Events [unstable angina or non-Q-wave myocardial infarction]
127. Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomized multicentre study
128. Combination therapy with tirofiban and enoxaparin in acute coronary syndromes
129. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes
130. Long-term oral anticoagulant therapy in patients with unstable angina or suspected non-Q-wave myocardial infarction: Organization to Assess Strategies for Ischemic Syndromes (OASIS) pilot study results
131. Progression of the culprit lesion in unstable coronary artery disease with warfarin and aspirin versus aspirin alone: Preliminary study
132. Direct thrombin inhibitors in cardiovascular medicine
133. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty: Helvetica Investigators
134. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina: Hirulog Angioplasty Study Investigators
135. Hirudin in acute myocardial infarction: Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial
136. A multicentre, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: Myocardial Infarction with Novastan and TPA (MINT) study
137. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischemia without ST elevation: A randomised trial
138. A low molecular weight, selective thrombin inhibitor, inogatran, vs heparin, in unstable coronary artery disease in 1,209 patients
139. Hirudin in acute myocardial infarction: Safety report from the Thrombolysis and Thrombi Inhibition in Myocardial Infarction (TIMI) 9A trial
140. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes
141. Safety observations from the pilot phase of the randomized r-hirudin for improvement of thrombolysis (HIT-III) study: A study from the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausarzte
142. Comparison of the effects of two doses of recombinant hirudin compared with heparin in patients with acute myocardial ischemia without ST elevation: A pilot study
143. Final report on the aspirin component of the ongoing Physicians' Health Study
144. Randomized trial of prophylactic daily aspirin in British male doctors
145. Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease
146. Hemostatic function and ischemic heart disease: Principal results of the Northwick Park Heart Study
147. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomized trial
148. Individualizing aspirin therapy for prevention of cardiovascular events
149. Aspirin and risk of hemorrhagic stroke
150. Who derives most benefit from aspirin in primary prevention?
151. A prospective study of aspirin use and primary prevention in cardiovascular disease in women
152. Baseline characteristics of participants in the Women's Health Study
153. Low-dose aspirin therapy for chronic stable angina: A randomized, placebo-controlled clinical trial
154. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with chronic angina pectoris